Document Detail

"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.
MedLine Citation:
PMID:  21595628     Owner:  NLM     Status:  MEDLINE    
Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL) subclasses. We sub-divided our statement in 2 sections. section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drug and lifestyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.
Dimitri P Mikhailidis; Moses Elisaf; Manfredi Rizzo; Kaspar Berneis; Bruce Griffin; Alberto Zambon; Vasilios Athyros; Jacqueline de Graaf; Winfried März; Klaus G Parhofer; Giovam Battista Rini; Giatgen A Spinas; Gerald H Tomkin; Alexandros D Tselepis; Anthony S Wierzbicki; Karl Winkler; Matilda Florentin; Evangelos Liberopoulos
Related Documents :
12965178 - Anti-cholesterol antibodies in human sera.
20869058 - Testosterone and cardiovascular disease: an old idea with modern clinical implications.
16759648 - Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque ...
16005008 - Cross-talk between dyslipidemia and renin-angiotensin system and the role of lox-1 and ...
15033328 - Effect of microcystin-lr on protein phosphatase activity in fed and fasted juvenile gol...
189158 - Turnover of apolipoprotein-b in two subjects with familial hypobetalipoproteinemia.
Publication Detail:
Type:  Consensus Development Conference; Journal Article    
Journal Detail:
Title:  Current vascular pharmacology     Volume:  9     ISSN:  1875-6212     ISO Abbreviation:  Curr Vasc Pharmacol     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-08-11     Completed Date:  2011-12-19     Revised Date:  2012-03-26    
Medline Journal Info:
Nlm Unique ID:  101157208     Medline TA:  Curr Vasc Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  533-71     Citation Subset:  IM    
Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atherosclerosis / blood*,  drug therapy,  epidemiology,  etiology*,  genetics
Genetic Predisposition to Disease
Lipoproteins, LDL / blood*,  classification*,  genetics
Risk Factors
Reg. No./Substance:
0/Lipoproteins, LDL

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  XDR-TB, What is it; How is it Treated; and Why is Therapeutic Failure so High?
Next Document:  Therapeutic interventions to renin-angiotensin-aldosterone system, and vascular redox state.